vimarsana.com
Home
Live Updates
FDA Issues Revised Guidance on Biosimilar Development and BP
FDA Issues Revised Guidance on Biosimilar Development and BP
FDA Issues Revised Guidance on Biosimilar Development and BPCIA | Goodwin
On September 20, 2021, the FDA issued a revised final guidance for industry entitled “Questions and Answers on Biosimilar Development and the BPCI Act” and a third revision to its draft...
Related Keywords
,
Biosimilar Development ,
Draftq As On Biosimilar Development ,